We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
The latest trading session saw Hologic (HOLX - Free Report) ending at $65.37, denoting a +0.4% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 1.2%. At the same time, the Dow added 1.58%, and the tech-heavy Nasdaq gained 1.16%.
Shares of the medical device maker have depreciated by 6.18% over the course of the past month, outperforming the Medical sector's loss of 7.05% and lagging the S&P 500's loss of 3.58%.
Investors will be eagerly watching for the performance of Hologic in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 9, 2023. The company's upcoming EPS is projected at $0.85, signifying a 3.66% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $941.4 million, down 1.25% from the year-ago period.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hologic. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 2.83% decrease. As of now, Hologic holds a Zacks Rank of #4 (Sell).
In the context of valuation, Hologic is at present trading with a Forward P/E ratio of 16.79. This indicates a discount in contrast to its industry's Forward P/E of 23.96.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 146, putting it in the bottom 43% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Gains But Lags Market: What You Should Know
The latest trading session saw Hologic (HOLX - Free Report) ending at $65.37, denoting a +0.4% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 1.2%. At the same time, the Dow added 1.58%, and the tech-heavy Nasdaq gained 1.16%.
Shares of the medical device maker have depreciated by 6.18% over the course of the past month, outperforming the Medical sector's loss of 7.05% and lagging the S&P 500's loss of 3.58%.
Investors will be eagerly watching for the performance of Hologic in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 9, 2023. The company's upcoming EPS is projected at $0.85, signifying a 3.66% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $941.4 million, down 1.25% from the year-ago period.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hologic. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 2.83% decrease. As of now, Hologic holds a Zacks Rank of #4 (Sell).
In the context of valuation, Hologic is at present trading with a Forward P/E ratio of 16.79. This indicates a discount in contrast to its industry's Forward P/E of 23.96.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 146, putting it in the bottom 43% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.